<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940425-2-00076</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>National Institutes of Health</USBUREAU> <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 -->  <DOCTITLE>Government-Owned Inventions; Availability for Licensing </DOCTITLE> <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> National Institutes of Health; HHS.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Notice. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </ACTION> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated Licensing Specialist at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, suite 325, Rockville, Maryland 20852&hyph;3804 (telephone 301/496&hyph;7735; fax 301/402&hyph;0220). A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Issued patents may be obtained from the Commissioner of Patents, U.S. Patent and Trademark Office, Washington, DC 20231.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=85 g=1 f=1 --> Attenuation of Ethyl Alcohol Intoxication With  <!-- PJG /ITAG -->  <!-- PJG ITAG l=85 g=6 f=1 --> a <!-- PJG /ITAG -->  <!-- PJG ITAG l=85 g=1 f=1 --> 2 Adrenoceptor Antagonists  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=15 g=1 f=1 --> Linnoila, M., Lister, R., Durcan, M. (NIAAA)  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Serial No. 07/512,835 (DIV of 07/294,119)  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> U.S. Patent No. 5,109,007 issued 28 Apr 92  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Licensing Specialist: Arthur J. Cohn  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> A new method of treating ethyl alcohol intoxication through the use of antagonists for the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=6 f=1 --> a <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 2 adrenoceptor has been discovered. Drugs based on these antagonists may have none of the potentially harmful sedative effects of the tranquilizers currently used.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=6 f=1 --> a <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 2 adrenoceptor agonists believed useful for this purpose include: atipamexole, idazoxan, imiloxan, yohimbine, Wyeth WY26703, Chinoin CH38083, Glaxo GR50360A, and Daiichi Seiyaku DG5128.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Rapid And Sensitive Test For Detecting Hepatitis A Virus  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=15 g=1 f=1 --> Robertson, B.H., Nainan, O.V., Brown, V.K., Margolis, H.S., Khanna, B. (CDC)  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Filed 31 Jan 92  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Serial No. 07/828,444 (CIP of 07/469,143)  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Licensing Specialist: Girish C. Barua  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> Diagnostic methods with improved sensitivity and specificity to hepatitis A virus (HAV) are needed. This novel assay can be used to test for general HAV infection as well as to differentiate between HAV genotype I, which is thought to be the most common HAV, and HAV genotype II, which differs genetically from HAV I (as well as HAV type III) by about 15%. Free HAV is removed from stool, environmental samples, and other materials by immunoselection of whole virus using high titer anti-HAV antibodies coated onto a solid phase; viral RNA is then denatured in the presence of primers that recognize all known HAV genotypes and that bind to viral RNA for reverse transcription into cDNA. PRC is used to amplify cDNA with  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Taq <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  polymerase using either labeled or unlabeled primers, depending on whether information on virus type is desired. This novel method is faster and more specific than currently available assays.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=85 g=1 f=1 --> Production of Isolated Proteinaceous Materials Using Recombinant Avipox Virus Vectors  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=15 g=1 f=1 --> Falkner, F.G., Dorner, F., Bodemer, W., Scheiflinger, F., Moss, B. (NIAID)  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Filed 11 May 92  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Serial No. 07/882,768 (CIP of 07/734,741, CIP of 07/339,738)  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Licensing Specialist: Girish C. Barua  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> This invention concerns the use of avipox viruses as vectors for the expression of foreign DNA in animal tissue culture. The viruses are constructed in the same convenient manner as recombinant vaccinia viruses, by recombination of a recombinant plasmid with wild type avipox virus. They have an advantage over vaccinia viruses in not being pathogenic for humans or mammals. The recombinant avipox viruses can, however, infect mammalian cell cultures as well as avian cell cultures.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Eukaryotic Expression Vector System  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=15 g=1 f=1 --> Giri, C.P., Ogawa, H., Harris, C.C. (NCI)  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Filed 22 Mar 93  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Serial No. 08/034,652  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Licensing Specialist: Carl C. Floyd, Ph.D.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> The method presented here allows for the enrichment of full length cDNAs of genes selected by their phenotypes. This is achieved by providing a vector system capable of synthesizing sense and antisense RNAs  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> in vitro <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  to generate RNA probes for use in an RNA:RNA hybridization based subtraction method. It also provides such an RNA:RNA hybridization based subtraction method for enrichment of the rare cDNs of interest. This will allow the selection of rare human cDNAs, for example, where limited amounts of cells are available.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=85 g=1 f=1 --> DNA Sequence Which Acts as a Chromatin Insulator Element To Protect Expressed Genes From Cis-Acting Regulatory Sequences  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=15 g=1 f=1 --> Chung, H.J. Felsenfeld, G. (NIDDK)  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Filed 7 Apr 93  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Serial No. 08/045,266  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Licensing Specialist: Carl C. Floyd, Ph.D.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> Novel method of insulating functional DNA domains introduced into higher eukaryotic cells from the effects of the cell's cis-acting regulatory elements. The invention represents the first pure insulator to be demonstrated to function in human cells. The element promises to be a useful tool in gene therapy, gene transfer techniques, and studies involving gene regulation and other gene expression technologies.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=85 g=1 f=1 --> Peptide Inhibitors of Protein Tyrosine Kinase_SH2 Interactions  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=15 g=1 f=1 --> Roller, P.P. Burke, T.R., Otaka, A., Nomizu, M. (NCI)  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Filed 8 Jun 93  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Serial No. 08/072,946  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Licensing Specialist: Carl C. Floyd, Ph.D.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> The invention relates to synthetic peptides which are inhibitors of protein-protein interactions, specifically that interaction between a protein having a src homology domain (SH2 domain) and a protein having a phosphorylated tyrosine that is recognized by the SH2 domain. This type of interaction occurs during cellular signal transduction cascades. These cascades are central in the regulation of cellular proliferation and therefore their control is of importance to chemotherapeutic approaches to antitumor therapy.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Phosphonoalkyl Phenylalanine Compounds Suitably Protected for Use In Peptide Synthesis  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=15 g=1 f=1 --> Burke, T.R., Smyth, M.S., Lim, B.B. (NCI)  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Filed 8 Jun 93  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Serial No. 08/073,088  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Licensing Specialist: Carl C. Floyd, Ph.D.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline --> </ADDRESS> <!-- PJG /STAG --></p>
		</main>
</body></html>
            